Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

SHVMS LLC published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 18, 2026 at 10:54 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]